ACM
TVRD

AlphaCrest Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

AlphaCrest Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-489
Closed -$266K – 1330
2020
Q4 		$266K Sell
489
-58
-11% -$30.4K 0.02% 960
2020
Q3 		$251K Buy
+547
New +$318K 0.03% 953
2019
Q2 		– Sell
-364
Closed -$257K – 1159
2019
Q1 		$257K Buy
+364
New +$218K 0.04% 705

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

AlphaCrest Capital Management's TVRD Position: Q1 2021 in Review

AlphaCrest Capital Management sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 489 shares — an estimated $266K sold.

AlphaCrest Capital Management first reported a position in TVRD in Q1 2019 and held it in 3 quarters. The position peaked at $266K in Q4 2020. 168 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • AlphaCrest Capital Management reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • AlphaCrest Capital Management sold 489 Tvardi Therapeutics shares in Q1 2021, an estimated $266K.
  • AlphaCrest Capital Management first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 3 quarters.
  • AlphaCrest Capital Management's Tvardi Therapeutics position peaked at $266K in Q4 2020.
  • 168 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on AlphaCrest Capital Management's 13F filing for Q1 2021, filed 13 May 2021.